In a strategic move to bolster its financial strategy and accelerate growth, bit.bio, a trailblazer in synthetic biology and human cell coding for novel therapies, has appointed Przemek Obloj as Chief Financial Officer. Obloj will lead the company’s financial operations, including fundraising initiatives, collaborating closely with Founder and CEO Mark Kotter and the executive team to drive bit.bio’s innovation and market expansion.

“Przemek brings a wealth of finance experience across the health and life sciences sectors,” said Mark Kotter, Founder and CEO of bit.bio. “His impressive track record, entrepreneurial drive, and connectivity with preeminent investment firms globally make him uniquely qualified to lead our financial strategy. Broadening our executive team will allow us to execute our growth strategy, scale our operations, and advance our position as a global leader in cell programming.”

Mr. Obloj’s career spans two decades of financial and investment experience in the health, life sciences, and technology sectors across Europe and North America. He has built two investment organizations, led growth and buyout transactions totaling $5 billion in equity investments, and facilitated over a dozen successful exits. Prior to joining bit.bio, Obloj was the Managing Partner and CIO at a Swiss family office and served as Managing Director and Head of European Private Equity at PSP Investments, a C$250 billion Canadian pension manager. His earlier career includes roles at CVC Capital Partners, EQT, and McKinsey & Company.

“There are few truly indispensable companies in the world, and I believe bit.bio is rapidly becoming one of them,” said Obloj. “When I met Mark four years ago, bit.bio was just starting to commercialize its breakthrough cell programming technology. Today, the company is emerging as a global leader in creating and manufacturing human cells with unmatched precision and scale, enabling step-change improvements in drug discovery, research, and ultimately cell therapies. We are on a path to making a positive difference for millions of patients while building a highly valuable business in the process. I am thrilled to join this exceptional team and help build the company towards its full potential.”